SCHEMBL189654

SCHEMBL189654

CCCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(NCC)nc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
HSD17B10 Q99714 4/20 0.50
GLA P06280 3/20 0.50
GAA P10253 2/20 0.50
MAPK1 P28482 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
PIK3CA P42336 16/20 0.43
CYP1A2 P05177 3/20 0.38
CLK4 Q9HAZ1 3/20 0.38
TSHR P16473 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CB P42338 1/20 0.37
MTOR P42345 1/20 0.37
PIK3CG P48736 1/20 0.37
USP2 O75604 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1899255 0.84 PIK3CA (0.53) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL189653 0.84 ALDH1A1 (0.45) ALDH1A1HSD17B10GLAGAAMAPK1
SCHEMBL189496 0.81 PIK3CA (0.66) PIK3CAMTOR
SCHEMBL12095760 0.79 CDK4 (0.42)
SCHEMBL3693426 0.77 ALDH1A1 (0.81) ALDH1A1HSD17B10GLAGAAMAPK1
SCHEMBL189497 0.76 PIK3CA (0.38) ALDH1A1HSD17B10GLAGAAMAPK1
Voxtalisib SCHEMBL3341496 0.75 PIK3CA (0.63) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL189391 0.73 ALDH1A1 (0.60) ALDH1A1HSD17B10GLAGAAMAPK1
SCHEMBL189326 0.72 ALDH1A1 (0.65) ALDH1A1HSD17B10GLAGAAMAPK1
SCHEMBL189483 0.71 ALDH1A1 (0.60) ALDH1A1HSD17B10GLAGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-B9 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-09-26 EP claimed
EP-2056829-B1 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-01-04 EP claimed